<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>ves_2015_25-1_ves-25-1-ves00549_ves-25-ves00549</title><style type="text/css"> * {margin:0; padding:0; text-indent:0; }
 .s1 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7pt; }
 .s2 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s3 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 25pt; }
 .s4 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 11pt; }
 .s5 { color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; vertical-align: 4pt; }
 .s6 { color: black; font-family:"Sitka Text"; font-style: italic; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s7 { color: black; font-family:Georgia, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s8 { color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s9 { color: black; font-family:"Bookman Old Style", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7pt; vertical-align: 3pt; }
 .s10 { color: black; font-family:"Times New Roman", serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 10pt; }
 h2 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 9pt; }
 .s11 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 .s12 { color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; vertical-align: 3pt; }
 .s13 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 h1 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 10pt; }
 .p, p { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; margin:0pt; }
 .a { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s14 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7pt; vertical-align: 3pt; }
 .s15 { color: black; font-family:"Times New Roman", serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s16 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: underline; font-size: 8pt; }
 .s17 { color: black; font-family:Verdana, sans-serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s18 { color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 li {display: block; }
 #l1 {padding-left: 0pt;counter-reset: c1 1; }
 #l1> li>*:first-child:before {counter-increment: c1; content: counter(c1, decimal)". "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 10pt; }
 #l1> li:first-child>*:first-child:before {counter-increment: c1 0;  }
 #l2 {padding-left: 0pt;counter-reset: c2 1; }
 #l2> li>*:first-child:before {counter-increment: c2; content: counter(c2, upper-latin)". "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l2> li:first-child>*:first-child:before {counter-increment: c2 0;  }
 #l3 {padding-left: 0pt;counter-reset: d1 1; }
 #l3> li>*:first-child:before {counter-increment: d1; content: "("counter(d1, decimal)") "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l3> li:first-child>*:first-child:before {counter-increment: d1 0;  }
 #l4 {padding-left: 0pt;counter-reset: e1 1; }
 #l4> li>*:first-child:before {counter-increment: e1; content: counter(e1, upper-latin)". "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l4> li:first-child>*:first-child:before {counter-increment: e1 0;  }
 #l5 {padding-left: 0pt;counter-reset: f1 1; }
 #l5> li>*:first-child:before {counter-increment: f1; content: "("counter(f1, decimal)") "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l5> li:first-child>*:first-child:before {counter-increment: f1 0;  }
 li {display: block; }
 #l6 {padding-left: 0pt;counter-reset: g1 4; }
 #l6> li>*:first-child:before {counter-increment: g1; content: counter(g1, decimal)" "; color: black; font-style: normal; font-weight: normal; text-decoration: none; }
 #l6> li:first-child>*:first-child:before {counter-increment: g1 0;  }
 #l7 {padding-left: 0pt;counter-reset: g2 1; }
 #l7> li>*:first-child:before {counter-increment: g2; content: counter(g1, decimal)"."counter(g2, decimal)". "; color: black; font-family:"Times New Roman", serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l7> li:first-child>*:first-child:before {counter-increment: g2 0;  }
 li {display: block; }
 #l8 {padding-left: 0pt;counter-reset: h1 1; }
 #l8> li>*:first-child:before {counter-increment: h1; content: "["counter(h1, decimal)"] "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 #l8> li:first-child>*:first-child:before {counter-increment: h1 0;  }
 #l9 {padding-left: 0pt;counter-reset: i1 13; }
 #l9> li>*:first-child:before {counter-increment: i1; content: counter(i1, upper-latin)". "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 #l9> li:first-child>*:first-child:before {counter-increment: i1 0;  }
 li {display: block; }
 #l10 {padding-left: 0pt;counter-reset: j1 1; }
 #l10> li>*:first-child:before {counter-increment: j1; content: counter(j1, decimal)". "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l10> li:first-child>*:first-child:before {counter-increment: j1 0;  }
 li {display: block; }
 #l11 {padding-left: 0pt;counter-reset: k1 1; }
 #l11> li>*:first-child:before {counter-increment: k1; content: counter(k1, upper-roman)". "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l11> li:first-child>*:first-child:before {counter-increment: k1 0;  }
</style></head><body><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s1" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Journal of Vestibular Research 25 (2015) 1–7 <span class="s2">1</span></p><p class="s1" style="padding-left: 5pt;text-indent: 0pt;line-height: 8pt;text-align: left;">DOI 10.3233/VES-150549</p><p class="s1" style="padding-left: 5pt;text-indent: 0pt;line-height: 8pt;text-align: left;">IOS Press</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Diagnostic criteria for Menière’s disease</p><p class="s4" style="padding-top: 22pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: left;">Jose A. Lopez-Escamez<span class="s5">a</span><span class="s6">,</span><span class="s7">k</span><span class="s6">,</span><span class="s8">∗</span>, John Carey<span class="s5">b</span>, Won-Ho Chung<span class="s5">c</span>, Joel A. Goebel<span class="s5">d</span>, Måns Magnusson<span class="s5">e</span>, Marco Mandalà<span class="s5">f </span>, David E. Newman-Toker<span class="s5">g</span>, Michael Strupp<span class="s5">h</span>, Mamoru Suzuki<span class="s5">i</span>, Franco Trabalzini<span class="s5">f </span>and Alexandre Bisdorff<span class="s5">j</span></p><p class="s9" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">a<span class="s10">Otology and Neurotology Group CTS495, Department of Genomic Medicine, Centre for Genomics and Oncology Research – Pfizer/Universidad de Granada/Junta de Andalucía (GENyO), PTS, Granada, Spain</span></p><p class="s9" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">b<span class="s10">Department of Otolaryngology, Head and Neck Surgery, John Hopkins University School of Medicine, Baltimore,</span></p><p class="s10" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">MD, USA</p><p class="s9" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">c<span class="s10">Department of Otolaryngology, Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan Univerisity School of Medicine, Seoul, Korea</span></p><p class="s9" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">d<span class="s10">Department of Otolaryngology, Head and Neck Surgery, Washington University School of Medicine, Saint Louis,</span></p><p class="s10" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">MO, USA</p><p class="s9" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">e<span class="s10">Department of Otolaryngology, University of Lund, Lund, Sweden</span></p><p class="s9" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">f <span class="s10">Otology and Skull Base Department, Azienda Ospedaliera Universitaria Senese, Siena, Italy</span></p><p class="s9" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">g<span class="s10">Department of Neurology, John Hopkins University School of Medicine, Baltimore, MD, USA</span></p><p class="s9" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">h<span class="s10">Department of Neurology and German Center for Vertigo and Balance Disorders, Ludwig-Maximilians University, Munich, Germany</span></p><p class="s9" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">i<span class="s10">Department of Otolaryngology, Tokyo Medical University, Tokyo, Japan</span></p><p class="s9" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">j<span class="s10">Department of Neurology, Centre Hospitalier Emile Mayrisch, Esch-sur-Alzette, Luxembourg</span></p><p class="s9" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">k<span class="s10">Department of Otolaryngology, Hospital de Poniente, El Ejido, Almeria, Spain</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-top: 9pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Received 2 March 2014</p><p class="s2" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Accepted 10 Feburary 2015</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;">Abstract. <span class="s11">This paper presents diagnostic criteria for Menière’s disease jointly formulated by the Classification Committee of the Bárány Society, The Japan Society for Equilibrium Research, the European Academy of Otology and Neurotology (EAONO), the Equilibrium Committee of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) and the Korean Balance Society. The classification includes two categories: definite Menière’s disease and probable Menière’s disease. The diagnosis of definite Menière’s disease is based on clinical criteria and requires the observation of an episodic vertigo syndrome associated with low- to medium-frequency sensorineural hearing loss and fluctuating aural symptoms (hearing, tinnitus and/or fullness) in the affected ear. Duration of vertigo episodes is limited to a period between 20 minutes and 12 hours. Probable Menière’s disease is a broader concept defined by episodic vestibular symptoms (vertigo or dizziness) associated with fluctuating aural symptoms occurring in a period from 20 minutes to 24 hours.</span></h2><p class="s11" style="padding-top: 9pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Keywords: Vertigo, sensorineural hearing loss, tinnitus, vestibular disorders, Meniere disease</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="290" height="1" alt="image" src="ves_2015_25-1_ves-25-1-ves00549_ves-25-ves00549/Image_001.png"/></span></p><p class="s12" style="padding-left: 5pt;text-indent: 7pt;text-align: justify;">∗<a href="mailto:antonio.lopezescamez@genyo.es" class="s13" target="_blank">Corresponding author: Jose A. Lopez-Escamez, Otology and Neurotology Group CTS495, GENyO, -Centre for Genomics and Oncological Research – Pfizer/Universidad de Granada/Junta de An- dalucía, PTS Avda de la Ilustracion, 114 18016 Granada, Spain. E-mail: antonio.lopezescamez@genyo.es.</a></p><h1 style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">List of acronyms</h1><p style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">AAO-HNS – American Academy Otolaryngology Head and Neck Surgery</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">CCBS – Classification Committee of the Bárány Soci- ety</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">EAONO – European Academy of Otology and Neuro- tology</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">ICVD – International Classification of Vestibular Dis-</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">ISSN 0957-4271/15/$35.00 <span class="s8">∗</span>c  2015 – IOS Press and the authors. All rights reserved</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">orders</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">MD – Meniere’s disease</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">SNHL – Sensorineural hearing loss MRI – Magnetic resonance imaging TIA – Transient ischemic attacks</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l1"><li><h1 style="padding-top: 10pt;padding-left: 18pt;text-indent: -12pt;text-align: left;">Introduction</h1><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 9pt;text-align: justify;"><a href="#bookmark0" class="a">Menière’s disease (MD) is a multifactorial disor- der where the combined effect of genetics and envi- ronmental factors probably determine the onset of the disease. It is associated with the accumulation of en- dolymph in the cochlear duct and the vestibular organs in histopathological studies  </a><a href="#bookmark1" class="a">[1], although endolym- phatic hydrops (EH) per se does not explain all clinical features, including the progression of hearing loss or the frequency of attacks of vertigo [</a>2]. Menière’s dis- ease is a clinical syndrome that consists of episodes of spontaneous vertigo usually associated with unilateral fluctuating sensorineural hearing loss (SNHL), tinnitus and aural fullness. Cochlear symptoms may also oc- cur between vertigo episodes. The episodes of vertigo are usually much more common in the first years of the disease, but hearing loss and vestibular hypofunc- tion show a great variability among patients, making the phenotyping of MD difficult. A taxonomy of MD subtypes is needed to help categorize individuals who manifest what may be incomplete phenotypes. More- over, subsets of patients have been described who de- velop bilateral SNHL and other co-morbidities such as migraine, benign paroxysmal positional vertigo and systemic autoimmune diseases, further complicating the diagnosis and management in these cases.</p><p style="padding-left: 5pt;text-indent: 9pt;text-align: justify;"><a href="#bookmark2" class="a">The Bárány Society, which represents the interna- tional community of basic scientists, otolaryngolo- gists, oto-neurologists, physical therapists and other experts committed to vestibular research, has set up a Classification Committee for an International Classifi- cation of Vestibular Disorders (ICVD). Individual dis- orders are defined by classification groups, which in- clude otolaryngologists and neurologists from at least three continents. The ICVD has been organized in 3 levels: signs and symptoms, vestibular syndromes and diseases. As a first step and prerequisite for defining major syndromes and diseases of the ICVD, the Classi- fication Committee of the Bárány Society (CCBS) has published a consensus on the definitions of vestibular symptoms </a>[3]. Further, a consensus document of the Bárány Society and the International Headache Soci- ety was published to define the diagnostic criteria of</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;"><a href="#bookmark3" class="a">vestibular migraine </a>[4]. Current ongoing works include definition for vestibular signs such as nystagmus, be- nign paroxysmal positional vertigo, unilateral and bi- lateral vestibulopathy and vestibular paroxysmia.</p><p style="padding-left: 5pt;text-indent: 9pt;text-align: justify;"><a href="#bookmark4" class="a">Different efforts have been sought to define in the past a consensus diagnosis for MD. The Japanese Society for Equilibrium Research proposed clinical criteria for diagnosis of MD in 1974 (Appendix 1). The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) developed the guidelines for diagnosis and therapy evaluation of MD in 1972 and revised them in 1985 and 1995 </a>[5]. These guide- lines have been widely used in clinical research, and nearly all studies published since 1995 are based on these criteria (Appendix 2). Despite the great contribu- tion of these guidelines to evaluate the effectiveness of medical and surgical treatments for MD, no biological marker for diagnosis or prognosis has been identified for MD so far, but an evolving understanding of MD and vestibular migraine – the most relevant differential diagnosis – points out the need to update these criteria. The clinical variability observed in MD makes it nec- essary to improve the precision to characterize clini- cal findings during and between the episodes of vertigo and the recognition of a familial history of hearing loss and episodic vertigo. These will lead to more homoge- neous cohorts of patients to conduct clinical multicen- ter studies, including large-scale genomic studies. The EAONO had also established a working group to pre- pare European guidelines for diagnosis and treatment of MD.</p><p style="padding-left: 5pt;text-indent: 9pt;text-align: justify;">The principal aim of this effort has been to develop international consensus diagnostic criteria for MD as part of the ongoing work of the CCBS to improve the quality of clinical data obtained from patients to facil- itate collaborative studies.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><h1 style="padding-top: 10pt;padding-left: 18pt;text-indent: -12pt;text-align: left;">Methods</h1><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 9pt;text-align: justify;">This work forms part of an ongoing multi-year project to develop an ICVD, which uses a structured process for developing international consensus defini- tions for vestibular symptoms, syndromes, disorders, and diseases. This process, overseen by the CCBS, is based on expert, multi-disciplinary committees with international representation developing diagnostic cri- teria for subsequent comment and refinement prior to publication. These criteria are built on a critical ap- praisal of current best scientific evidence. A collab- orative work among the Equilibrium Committee of</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">the AAO-HNS, the Japan Society for Equilibrium Re- search, the EAONO, the Korean Balance Society and the Bárány Society has been established for joint devel- opment of diagnostic criteria for MD. All definitions are supported by notes, comments, and written discus- sion according to a template established by the CCBS for ICVD. MD criteria were developed iteratively over a four-year period (2010–14) through discussion, pre- sentation, and refinement. Two diagnostic categories were considered: definite and probable MD. The pri- mary adjustments to prior criteria were to clarify the nature of auditory symptoms and signs present for def- inite MD.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><h1 style="padding-top: 7pt;padding-left: 18pt;text-indent: -12pt;text-align: left;">Criteria for diagnosis of Menière’s disease</h1><p class="s10" style="padding-top: 9pt;padding-left: 5pt;text-indent: 9pt;text-align: left;">Previously used terms<span class="p">: Menière’s syndrome, en- dolymphatic hydrops (EH)</span></p><p class="s10" style="padding-top: 9pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Definite MD</p><ol id="l2"><li><p style="padding-top: 9pt;padding-left: 30pt;text-indent: -14pt;line-height: 94%;text-align: justify;">Two or more spontaneous episodes of vertigo<span class="s14">(1,2)</span>, each lasting 20 minutes to 12 hours<span class="s14">(3)</span>.</p></li><li><p style="padding-left: 30pt;text-indent: -14pt;text-align: justify;">Audiometrically documented low- to medium- frequency sensorineural hearing loss<span class="s14">(4,5) </span>in one ear, defining the affected ear on at least one oc- casion before, during or after one of the episodes of vertigo<span class="s14">(6,7)</span>.</p></li><li><p style="padding-left: 30pt;text-indent: -14pt;text-align: justify;">Fluctuating aural symptoms (hearing, tinnitus or fullness) in the affected ear<span class="s14">(8)</span>.</p></li><li><p style="padding-left: 30pt;text-indent: -14pt;text-align: justify;">Not better accounted for by another vestibular diagnosis<span class="s14">(9)</span>.</p><p class="s10" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Notes:</p><ol id="l3"><li><p style="padding-top: 2pt;padding-left: 32pt;text-indent: -16pt;text-align: justify;"><a href="#bookmark2" class="a">Vertigo is the sensation of self-motion when no self-motion is occurring or the sensation of dis- torted self-motion during an otherwise normal head movement </a>[3]. Episodic dizziness and un- steadiness are not considered as criteria to de- fine MD, although patients with MD can report dizziness and unsteadiness at long term.</p></li><li><p style="padding-left: 32pt;text-indent: -16pt;text-align: justify;">Although most patients report entirely sponta- neous spells of vertigo, some patients identify dietary triggers, such as excessive consumption of sodium or caffeine. Some patients can ex- perience episodes of vertigo lasting seconds to minutes triggered by high intensity and low- frequency sound (Tullio phenomenon) and by changes in pressure. These episodes tend to occur later in the disease, perhaps as a result of advanced hydrops bringing the membranous labyrinth in close proximity to the stapes foot- plate.</p></li><li><p style="padding-top: 4pt;padding-left: 22pt;text-indent: -16pt;text-align: justify;"><a href="#bookmark5" class="a">The duration of the episodes is defined by the time that the patient has to be on rest and cannot move. It may last less than 20 minutes or more than 12 hours, but neither is a common find- ing, and other disorders should be considered when such durations are noted </a>[6]. When short episodes occur they are usually spontaneous. Brief episodes triggered by positional changes of the head should suggest other causes such as BPPV. The duration of an episode may be difficult to define as patients may have residual symptoms after an episode.</p></li><li><p style="padding-left: 22pt;text-indent: -16pt;text-align: justify;">The affected ear is determined by hearing loss defined in criteria B. Low-frequency SNHL is defined as increases in pure tone thresholds for bone-conducted sound that are higher (i.e., worse) in the affected ear than the contralat- eral ear by <i>at least 30 dB HL at each of two contiguous frequencies below 2000 Hz</i><a href="#bookmark6" class="a">. In cases of bilateral low-frequency SNHL, the absolute thresholds for bone-conducted sound must be 35 dB HL or higher at each of two contiguous frequencies below 2000 Hz. If multiple audio- grams are available, demonstration of recovery of low-frequency SNHL at some point in time further supports the diagnosis of MD. Bilateral synchronous SNHL (symmetric or asymmetric) can occur in some patients </a><a href="#bookmark7" class="a">[7–</a><a href="#bookmark8" class="a">9], although such a pattern should raise concern for the possibility of autoimmune inner ear disease [</a><a href="#bookmark9" class="a">10] and when progressing slowly over years, may favor mi- graine as an alternate explanation for the vertigo episodes or a comorbid condition [</a><a href="#bookmark10" class="a">11]. Bilateral low-frequency SNHL can also been observed in early stages of non-syndromic progressive deaf- ness (DFNA6/14) due to mutations in the WFS1 gene, but vertigo attacks have not been associ- ated with this group of mutations [</a>12]. SNHL in MD can also involve middle and high frequen- cies after several episodes of vertigo, leading to pan-tonal hearing loss.</p></li><li><p style="padding-left: 22pt;text-indent: -16pt;text-align: justify;"><a href="#bookmark11" class="a">Non-simultaneous onset of vertigo and hear- ing loss. Sensorineural hearing loss may ante- date the onset of vertigo episodes by several months or years. This clinical variant has been called “delayed hydrops” </a><a href="#bookmark12" class="a">[13</a>,14], but the pre- ferred term should be <i>delayed MD</i>, since EH is a pathological finding. Episodic vertigo may pre- cede the onset of hearing loss by several weeks or months, but tinnitus or aural fullness is usu- ally associated with the first episode of vertigo.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-top: 7pt;padding-left: 32pt;text-indent: -16pt;text-align: justify;">A temporal association between hearing loss and the vertigo episode is sometimes observed by the patient, generally as a change in hearing within 24 hours of the vertigo episode. Hear- ing loss typically fluctuates spontaneously in the first few years of the disease. After repeated at- tacks, the hearing loss may progress and be- come permanent, and the episodes of vertigo may likewise no longer be related with the aural symptoms.</p></li><li><p style="padding-left: 32pt;text-indent: -16pt;text-align: justify;"><a href="#bookmark13" class="a">Attacks of sudden loss of vestibulo-spinal re- flexes resulting in sudden falls or less often latero-pulsion and lasting seconds or, rarely, a few minutes can occur (so called drop vestibular attacks, otolithic crises or Tumarkin’s otolithic crises) </a><a href="#bookmark14" class="a">[15</a>,16].</p></li><li><p style="padding-left: 32pt;text-indent: -16pt;text-align: justify;">An increase in tinnitus intensity or aural full- ness in the affected ear is often associated with the episode of vertigo in the first years. Tinni- tus may be persistent once the hearing loss has become permanent.</p></li><li><p style="padding-left: 32pt;text-indent: -16pt;text-align: justify;">The differential diagnosis should include tran- sient ischemic attack, vestibular migraine, vesti- bular paroxysmia, recurrent unilateral vestibu- lopathy and other vestibular disorders. MRI may be required to exclude vestibular schwannoma or endolymphatic sac tumor. Migraine, benign paroxysmal positional vertigo and some forms of systemic autoimmune conditions are consid- ered co-morbidities and do not explain the diag- nosis of MD. See Comments for discussion of specific differential diagnoses.</p></li></ol><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s10" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Probable MD</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l4"><li><p style="padding-left: 30pt;text-indent: -14pt;text-align: left;">Two or more episodes of vertigo or dizziness, each lasting 20 minutes to 24 hours.</p></li><li><p style="padding-left: 30pt;text-indent: -14pt;text-align: left;">Fluctuating aural symptoms (hearing, tinnitus or fullness) in the affected ear<span class="s14">(1)</span>.</p></li></ol><p style="padding-left: 30pt;text-indent: -14pt;text-align: left;">D. Not better accounted for by another vestibular diagnosis<span class="s14">(2)</span>.</p><p class="s10" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Notes:</p><ol id="l5"><li><p style="padding-top: 3pt;padding-left: 32pt;text-indent: -16pt;text-align: justify;">Fluctuating symptoms must be reported during the vertigo episode. Sensorineural hearing loss is usually found, but conductive or mixed hear- ing loss may be also observed in the first years of the disease. An increase in tinnitus intensity or aural fullness in the affected ear is usually as- sociated with the episode of vertigo in the first years.</p><p class="s2" style="padding-top: 4pt;padding-left: 165pt;text-indent: 0pt;text-align: center;">Table 1</p><p class="s2" style="padding-bottom: 3pt;padding-left: 165pt;text-indent: 0pt;text-align: center;">Differential diagnosis of Menière’s disease</p><p style="padding-left: 6pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="287" height="1" alt="image" src="ves_2015_25-1_ves-25-1-ves00549_ves-25-ves00549/Image_002.png"/></span></p><p class="s2" style="padding-left: 8pt;text-indent: 0pt;text-align: left;">Autosomal dominant sensorineural hearing loss type 9 (DFNA9) caused by <i>COCH </i>gene</p><p class="s2" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">Autosomal dominant sensorineural hearing loss type 6/14 (DFNA6/14) caused by WSF1 gene</p><p class="s2" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">Autoimmune inner ear disease</p><p class="s2" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">Cerebrovascular disease (stroke/TIA in the vertebrobasiliar sys- tem/bleeding)</p><p class="s2" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;line-height: 130%;text-align: left;">Cogan‘s syndrome. Some cases may have recurrences. Endolymphatic sac tumor</p><p class="s2" style="padding-left: 8pt;text-indent: 0pt;line-height: 130%;text-align: left;">Meningiomas and other masses of the cerebellopontine angle Neuroborreliosis</p><p class="s2" style="padding-left: 8pt;text-indent: 0pt;line-height: 130%;text-align: left;">Otosyphilis Susac syndrome</p><p class="s2" style="padding-left: 8pt;text-indent: 0pt;text-align: left;">Third window syndromes (Perilymph fistula, canal dehiscence, en- larged vestibular aqueduct)</p><p class="s2" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">Vestibular migraine</p><p class="s2" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;line-height: 129%;text-align: left;">Vestibular paroxysmia (neurovascular compression syndrome) Vestibular schwannoma</p><p class="s16" style="padding-left: 6pt;text-indent: 0pt;text-align: left;"> Vogt-Koyanagi-Harada syndrome                                                     </p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 32pt;text-indent: -16pt;text-align: justify;">The differential diagnosis should include tran- sient ischemic attack, vestibular migraine and other vestibular disorders. MRI may be required to exclude vestibular schwannoma or endolym- phatic sac tumor. Migraine, benign paroxys- mal positional vertigo and some forms of sys- temic autoimmune conditions are considered <i>co-morbidities </i>and do not explain the clinical syndrome of MD. See <i>Comments </i>for discussion of specific differential diagnoses.</p></li></ol><p style="text-indent: 0pt;text-align: left;"><br/></p></li></ol></li><li><h1 style="padding-left: 18pt;text-indent: -12pt;text-align: left;">Comments</h1></li></ol><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l6"><ol id="l7"><li><p class="s10" style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Epidemiology</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 15pt;text-indent: 0pt;text-align: justify;">The prevalence of MD is approximately 34–190 per</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;"><a href="#bookmark15" class="a">100.000 </a><a href="#bookmark16" class="a">[17–19]. The age of onset ranges from the third to the seventh decades of life with a small female predominance. The odds of MD are greater for older subjects (adjusted OR per 10-year increase: 1.5), white ethnicity (OR 1.7) and severe obesity (OR 1.7) [19]. Furthermore, MD is associated with several comorbid conditions such as arthritis (OR 1.8), psoriasis (OR 1.8), gastroesophageal reflux disease (OR 1.5), irri- table bowel syndrome (OR 2.1) and migraine (OR 2.0) </a><a href="#bookmark17" class="a">[19]. MD is characterized by a variable course, and the development of cochlear and vestibular symp- toms may take years in individual patients [</a>20]. A list of disorders mimicking MD is presented in Table 1.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p class="s10" style="padding-top: 4pt;padding-left: 25pt;text-indent: -19pt;text-align: left;">Endolymphatic hydrops (EH)</p><p style="padding-top: 9pt;padding-left: 5pt;text-indent: 9pt;text-align: justify;"><a href="#bookmark1" class="a">Histopathological studies in human temporal bones have found EH in most patients with MD </a><a href="#bookmark17" class="a">[1,2]. The re- cent development of 3 T MRI with gadolinium chelate has allowed the visualization of EH in 93% of ears with symptoms attributable to MD, but also in 65% of asymptomatic contralateral ears [</a><a href="#bookmark18" class="a">20]. In addition, elec- trocochleography is a neurophysiological test that cor- relates with EH in the cochlea; however, the fluctuating symptoms limit their applicability as diagnostic tool in the early course of MD </a>[21].</p></li><li><p class="s10" style="padding-top: 9pt;padding-left: 25pt;text-indent: -19pt;text-align: left;">Familial MD</p><p style="padding-top: 9pt;padding-left: 5pt;text-indent: 9pt;text-align: justify;"><a href="#bookmark19" class="a">Familial MD should be considered if at least one other relative (first or second degree) fulfills all the cri- teria of definite or probable MD [22]. Familial MD is observed in 8%–9% of sporadic cases in populations of European descent [</a><a href="#bookmark20" class="a">22</a><a href="#bookmark21" class="a">,23]. It has been described in Caucasians from United Kingdom </a><a href="#bookmark22" class="a">[24], Brazil [</a><a href="#bookmark23" class="a">25], Sweden </a><a href="#bookmark20" class="a">[26], Finland </a><a href="#bookmark24" class="a">[23,</a><a href="#bookmark25" class="a">27], Germany [</a><a href="#bookmark20" class="a">28] and Spain [</a><a href="#bookmark19" class="a">23]. Although most families described have an autosomal dominant pattern of inheritance, famil- ial MD shows genetic heterogeneity, and mitochon- drial and recessive inheritance patterns are also ob- served in some families [</a><a href="#bookmark26" class="a">22]. Mutations in DTNA and FAM136A genes have been described in familial MD [</a>29]. A family history of SNHL, migraine or re- current vertigo in several members of the family would justify a familial investigation of these patients to con- firm if any of them fulfill diagnostic criteria for MD.</p></li><li><p class="s10" style="padding-top: 9pt;padding-left: 25pt;text-indent: -19pt;text-align: left;">Overlap with vestibular migraine</p><p style="padding-top: 9pt;padding-left: 5pt;text-indent: 9pt;text-align: justify;"><a href="#bookmark27" class="a">Some studies suggest that migraine is more common in patients with MD than in healthy controls </a><a href="#bookmark28" class="a">[30,</a><a href="#bookmark29" class="a">31]. Patients with features of both MD and vestibular mi- graine have been repeatedly reported [</a><a href="#bookmark30" class="a">32]. In fact, mi- graine and MD can be inherited as a symptom clus- ter [</a><a href="#bookmark29" class="a">33]. Fluctuating hearing loss, tinnitus and aural pressure may occur in vestibular migraine, but SNHL does not typically progress to severe hearing loss over the years in migraine. When hearing loss develops in vestibular migraine, it is often bilateral [</a><a href="#bookmark31" class="a">32] whereas involvement of both ears from the onset is rare in MD </a><a href="#bookmark32" class="a">[34]. Although migraine headache and phonopho- bia may be present during MD attacks, the pathophys- iological relationship between vestibular migraine and MD is unclear. Some authors have suggested a com- mon pathophysiology, perhaps linked to an ion chan- nel dysfunction [</a><a href="#bookmark33" class="a">35] and endolymphatic hydrops has been reported in patients with vestibular migraine and auditory symptoms [</a>36].</p></li><li><p class="s10" style="padding-top: 4pt;padding-left: 25pt;text-indent: -19pt;text-align: left;">Autoimmune inner ear disease</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 9pt;text-align: justify;"><a href="#bookmark34" class="a">Autoimmune inner ear disease (AIED) is a syn- drome of rapidly progressive, often fluctuating, bilat- eral SNHL over a period of days to months. Vestibu- lar symptoms may be present in almost 50% of pa- tients, and a systemic autoimmune disease coexists in 15%–30% of patients </a><a href="#bookmark35" class="a">[37]. In some cases, AIED be- gins as sudden SNHL in one ear progressing rapidly to the second ear with tinnitus and balance symptoms, which may resemble MD </a>[38]. Rare cases of otologic syphilis and neuroborreliosis can present similarly.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p class="s10" style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Transient ischemic attack and stroke</p></li></ol></ol><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 9pt;text-align: justify;"><a href="#bookmark36" class="a">Combined audio-vestibular symptoms are also a hallmark of transient ischemic attack (TIA) and stroke, since the blood supply to the inner ear derives from the vertebro-basilar circulation </a><a href="#bookmark37" class="a">[39]. Such symptoms typically result from ischemia in the anterior inferior cerebellar artery (AICA) territory </a><a href="#bookmark38" class="a">[40,</a><a href="#bookmark39" class="a">41], since the internal auditory artery (IAA) most often arises as a branch of the AICA. However, the IAA can arise di- rectly from the basilar artery in 15%–20% of individ- uals [</a>42], so mixed vestibular and auditory symptoms may be a harbinger of basilar artery occlusion.</p><p style="padding-left: 5pt;text-indent: 9pt;text-align: justify;"><a href="#bookmark40" class="a">Patients may present initially with transient or episo- dic symptoms (TIA) that culminate in stroke with acute permanent hearing loss, permanent vestibular loss, or both </a><a href="#bookmark37" class="a">[43]. Transient dizziness, hearing loss, and/or tinnitus may occur as a premonitory TIA pre- ceding acute audio-vestibular loss due to AICA infarc- tion in up to 42% of cases. [</a><a href="#bookmark40" class="a">40</a><a href="#bookmark41" class="a">,43] Although neuro- logic symptoms such as facial palsy or hemiparesis can occur in patients with basilar strokes, some pa- tients with partial syndromes can manifest with iso- lated audio-vestibular symptoms almost indistinguish- able from MD [</a><a href="#bookmark42" class="a">44]. Furthermore, TIA symptoms can culminate in isolated labyrinthine infarction (without cerebellar or brainstem involvement) [</a>45].</p><p style="padding-left: 5pt;text-indent: 9pt;text-align: justify;"><a href="#bookmark42" class="a">Most strokes after TIA occur within 90 days </a>[45], but isolated vestibular symptoms have been reported for up to two years or more preceding stroke. There- fore, great care should be taken in patients with symp- toms that are very recent in total illness duration (<span class="s17">&lt; </span>3 months–6 months, especially <span class="s17">&lt; </span>30 days), particu- larly if the total number of episodes is relatively small (e.g., <span class="s17">&lt; </span><a href="#bookmark41" class="a">5) or has followed an escalating temporal pro- file of episode frequency (“crescendo TIA”) [</a>44]. Care should also be taken in patients with known vascular risk factors (including older age at first onset) and those</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;">presenting to acute care settings such as the emergency department. When clinically-important doubt exists, appropriate diagnostic testing for stroke and TIA (e.g., MRI with magnetic resonance angiography) should be considered. The first episode of MD may not differ from a TIA, and sudden SNHL associated with vertigo may be caused by a labyrinthine infarction.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Acknowledgments</h1><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 9pt;text-align: justify;">The Barany Society, the EAONO and Neuro<span class="s18">+</span>, Berlin have supported the working meetings to develop a consensus definition for MD. The authors are thank-</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;">ful for all the comments and suggestions received from the vestibular community worldwide.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: left;">References</h1><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l8"><li><p class="s2" style="padding-left: 27pt;text-indent: -17pt;text-align: justify;"><a name="bookmark0">S.D. Rauch, S.N. Merchant and B.A. Thedinger, Menière’s syndrome and endolymphatic hydrops: Double-blind tempo- ral bone study, </a><i>Ann Otol Rhinol Laryngol </i><b>98 </b>(1989), 873–883.<a name="bookmark1">&zwnj;</a></p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -17pt;text-align: justify;"><a name="bookmark2">S.N. Merchant, J.C. Adams and J.B. Nadol, Pathophysiol- ogy of Menière’ syndrome are symptoms caused by endolym- phatic hydrops? </a><i>Otol Neurotol </i><b>26 </b>(2005), 74–81.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -17pt;text-align: justify;"><a name="bookmark3">A. Bisdorff, M. von Brevern, T. Lempert and D. Newman- Toker (on behalf of the committee for the classification of vestibular disorders of the Bárány society), classification of vestibular symptoms: Towards an international classification of vestibular disorders, </a><i>J Vest Res </i><b>19 </b>(2009), 1–13.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -17pt;text-align: justify;"><a name="bookmark4">T. Lempert, J. Olesen, J. Furman, J. Waterston, B. Seemun- gal, J. Carey et al., Vestibular migraine: Diagnostic criteria, </a><i>J Vestib Res </i><b>22 </b>(2012), 167–172.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -17pt;text-align: justify;"><a name="bookmark5">Committee on hearing and equilibrium, guidelines for the di- agnosis and evaluation of therapy in Menière’s disease, </a><i>Oto- laryngol Head Neck Surg </i><b>113 </b>(1995), 181–185.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -27pt;text-align: right;">H. Perez-Garrigues, J.A. Lopez-Escamez, P. Perez, R. Sanz,</p><ol id="l9"><li><p class="s2" style="padding-left: 38pt;text-indent: -38pt;text-align: right;">Orts, J. Marco, R. Barona, M.C. Tapia, I. Aran, C. Cenjor,</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: 0pt;text-align: justify;"><a name="bookmark6">Perez, C. Morera and R. Ramirez, Time course of episodes of definitive vertigo in Menière’s disease, </a><i>Arch Otolaryngol Head Neck Surg </i><b>134 </b>(2008), 1149–1154.</p></li></ol></li><li><p class="s2" style="padding-left: 27pt;text-indent: -17pt;text-align: justify;">S. Nabi and L.S. Parnes, Bilateral Ménière’s disease, <i>Curr Opin Otolaryngol Head Neck Surg </i><b>17 </b>(2009), 356–362.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -17pt;text-align: justify;"><a name="bookmark7">J.A. Lopez-Escamez, D. Viciana and P. Garrido-Fernandez, Impact of bilaterality and headache on health-related quality of life in Menière’s disease, </a><i>Ann Otol Rhinol Laryngol </i><b>118 </b>(2009), 409–416.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -17pt;text-align: justify;"><a name="bookmark8">A. Belinchon, H. Perez-Garrigues, J.M. Tenias and A. Lopez, Hearing assessment in Menière’s disease, </a><i>Laryngoscope </i><b>121 </b>(2011), 622–626.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark9">S. Pathak, L.J. Hatam, V. Bonagura and A. Vambutas, Innate immune recognition of molds and homology to the inner ear protein, cochlin, in: </a><i>Patients with Autoimmune Inner Ear Dis- ease, J Clin immunol </i><b>33 </b>(2013), 1204–1215.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;">Y.H. Cha, J. Brodsky, G. Ishiyama, C. Sabatti and R.W. Baloh, The relevance of migraine in patients with Menière’s disease, <i>Acta Otolaryngol </i><b>127 </b>(2007), 1241–1245.</p></li><li><p class="s2" style="padding-top: 6pt;padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark10">R.J. Pennings, S.J. Bom, K. Cryns, K. Flothmann, P.L. Huy- gen, H. Kremer, G. Van Camp and C.W. Cremers, </a><i>Progres- sion of Low-Frequency Hearing Loss Sensorineural Hearing Loss (DFNA6/14-WFS1) Arch Otolaryngol Head Neck Surg </i><b>129 </b>(2003), 421–426.<a name="bookmark11">&zwnj;</a></p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark12">H.F. Schuknecht, Y. Suzuka and C. Zimmermann, Delayed endolymphatic hydrops and its relationship to Meniére’s dis- ease, </a><i>Ann Otol Rhinol Laryngol </i><b>99 </b>(1990), 843–853.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;">T. Kamei, Delayed endolymphatic hydrops as a clinical entity,</p><p class="s15" style="padding-left: 27pt;text-indent: 0pt;text-align: justify;"><a name="bookmark13">Int Tinnitus J </a><b>10 </b><span class="s2">(2004), 137–143.</span></p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark14">E. Kentala, M. Havia and I. Pyykkö, Short-lasting drop at- tacks in Menière’s disease, </a><i>Otolaryngol Head Neck Surg </i><b>124 </b>(2001), 526–530.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;">N. Perez-Fernandez, L. Montes-Jovellar, J. Cervera-Paz and</p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;text-align: justify;"><a name="bookmark15">E. Domenech-Vadillo, Auditory and vestibular assessment of patients with Ménière’s disease who suffer Tumarkin attacks, </a><i>Audiol Neurootol </i><b>15 </b>(2010), 399–406.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;">H. Shojaku, Y. Watanabe, M. Fujisaka et al., Epidemiologic characteristics of definite Menière’s disease in Japan, a long- term survey of toyama and niigata prefectures, <i>ORL J Otorhi- nolaryngol Relat Spec </i><b>67</b>(5) (2005), 305–309.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark16">T.H. Alexander and J.P. Harris, Epidemiology of Menière’s syndrome, </a><i>Otolaryngol Clin N Am </i><b>43 </b>(2010), 965–970.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark17">J.S. Tyrrell, D.J.D. Whinney, O.C. Ukoumunne, L.E. Flem- ing and N.J. Osborne, Prevalence, associated factors and co- morbid conditions for Ménière’s disease, </a><i>Ear and Hearing </i><b>35 </b>(2014), e162–e169.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark18">I. Pyykko˝, T. Nakashima, T. Yoshida, J. Zou and S. Naganawa, Meniere’s disease: A reappraisal supported by a variable  la- tency  of  symptoms  and  the  MRI  visualisation  of  endolym- phatic hydrops, </a><i>BMJ Open </i><b>3</b>(2) (2013), e001555.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark19">P. Lamounier, D.A. Gobbo, T.S.A. de Souza, C.A.C.P. de Oliveira and F. Bahmad, Electrocochleography for Ménière’s disease: Is it reliable? </a><i>Braz J Otorhinolaryngol </i><b>80 </b>(2014), 527–532.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;">T. Requena, J.M. Espinosa-Sanchez, S. Cabrera, G. Trinidad,</p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;text-align: justify;"><a name="bookmark20">A. Soto-Varela, S. Santos-Perez et al., Familial clustering and genetic heterogeneity in Menière’s disease, </a><i>Clinical Genetics </i><b>85 </b>(2014), 245–252.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark21">E. Hietikko, J. Kotimäki, M. Sorri and M. Männikkö, High incidence of Menière-like symptoms in relatives of Menière patients in the areas of oulu university hospital and kainuu central hospital in finland, </a><i>Eur J Med Genet </i><b>56 </b>(2013), 179– 185.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark22">A.W. Morrison, M.E. Bailey and G.A. Morrison, Familial Ménière’s disease: Clinical and genetic aspects, </a><i>J Laryngol Otol </i><b>123 </b>(2009), 29–37.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark23">C.A. Oliveira, C.I. Messias and I. Ferrari, Occurrence of fa- milial Ménière’s syndrome and migraine in Brasilia, </a><i>Ann Otol Rhinol Laryngol </i><b>111 </b>(2002), 229–236.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark24">D. Gabrikova, C. Frykholm, U. Friberg, S. Lahsaee, M. En- tesarian, N. Dahl and J. Klar, Familiar Menière’s disease re- stricted to 1.48 Mb on chromosome 12p12.3 by allelic and haplotype association, </a><i>J Hum Genet </i><b>55 </b>(2010), 834–837.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark25">E. Hietikko, J. Kotimäki, E. Kentala, T. Klockars, M. Sorri and M. Männikkö, Finnish familial Menière disease is not linked to chromosome 12p12.3, and anticipation and cosegre- gation with migraine are not common findings, </a><i>Genet Med </i><b>13 </b>(2011), 415–420.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark26">D. Arweiler-Harbeck, B. Horsthemke, K. Jahnke and H.C. Hennies, Genetic aspects of familial Menière’s disease, </a><i>Otol Neurotol </i><b>32 </b>(2011), 695–700.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;">T. Requena, S. Cabrera, C. Martín-Sierra, S.D. Price, A. Lysakowski and J.A. Lopez-Escamez, Identification of two</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-top: 6pt;padding-left: 27pt;text-indent: 0pt;text-align: justify;"><a name="bookmark27">novel mutations in FAM136A and DTNA genes in autosomal- dominant familial Meniere’s disease, </a><i>Hum Mol Genet </i><b>24 </b>(2015), 1119–1126.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark28">A. Radtke, T. Lempert, M.A. Gresty, G.B. Brookes, A.M. Bronstein and H. Neuhauser, Migraine and Menière’s disease: Is there a link? </a><i>Neurology </i><b>59 </b>(2002), 1700–1704.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark29">Q. Gopen, E. Virre and J. Anderson, Epidemiologic study to explore links between Ménière syndrome and migraine headache, </a><i>Ear Nose Throat J </i><b>88 </b>(2009), 1200–1204.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;">A. Radtke, H. Neuhauser, M. von Brevern, T. Hottenrott and</p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;text-align: justify;"><a name="bookmark30">T. Lempert, Vestibular migraine-validity of clinical diagnostic criteria, </a><i>Cephalalgia </i><b>31 </b>(2011), 906–913.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark31">Y.H. Cha, M.J. Kane and R.W. Baloh, Familial clustering of migraine, episodic vertigo and Menière’s disease, </a><i>Otol Neu- rotol </i><b>29 </b>(2008), 93–96.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark32">D. Huppert, M. Strupp and T. Brandt, Long-term course of Menière’s disease revisited, </a><i>Acta Otolaryngol </i><b>130 </b>(2010), 644–651.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark33">P. Gates, Hypothesis: Could Menière’s disease be a chan- nelopathy? </a><i>Intern Med J </i><b>35 </b>(2005), 488–489.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark34">R. Gürkov, C. Kantner, M. Strupp, W. Flatz, E. Krause and B. Ertl-Wagner, Endolymphatic hydrops in patients with vestibu- lar migraine and auditory symptoms, </a><i>Eur Arch Otorhino- laryngol </i><b>271 </b>(2014), 2661–2667.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark35">R. Bovo, C. Aimoni and A. Martini, Immune-mediated inner ear disease, </a><i>Acta Otolaryngol </i><b>126 </b>(2006), 1012–1021.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark36">B.F. McCabe, Autoimmune sensorineural hearing loss, </a><i>Ann Otol Rhinol Laryngol </i><b>88 </b>(1979), 585–589.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark37">J.G. Oas and R.W. Baloh, Vertigo and the anterior inferior cerebellar artery syndrome, </a><i>Neurology </i><b>42 </b>(1992), 2274–2279.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;">H. Lee, S.I. Sohn, D.K. Jung, Y.W. Cho, J.G. Lim, S.D. Yi,</p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;text-align: justify;"><a name="bookmark38">S.R. Lee, C.H. Sohn and R.W. Baloh, Sudden deafness and anterior inferior cerebellar artery infarction, </a><i>Stroke </i><b>33 </b>(2002), 2807–2812.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark39">H. Lee and R.W. Baloh, Sudden deafness in vertebrobasilar is- chemia: Clinical features, vascular topographical patterns and long-term outcome, </a><i>J Neurol Sci </i><b>228 </b>(2005), 99–104.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;">R. Häusler and R.A. Levine, Auditory dysfunction in stroke,</p><p class="s15" style="padding-left: 27pt;text-indent: 0pt;text-align: justify;"><a name="bookmark40">Acta Otolaryngol </a><b>120 </b><span class="s2">(2000), 689–703.</span></p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark41">H. Lee, Neuro-otological aspects of cerebellar stroke syn- drome, </a><i>J Clin Neurol </i><b>5 </b>(2009), 65–73.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;"><a name="bookmark42">H. Lee and Y.W. Cho, Auditory disturbance as a prodrome of anterior inferior cerebellar artery infarction, </a><i>J Neurol Neuro- surg Psychiatry </i><b>74 </b>(2003), 1644–1648.</p></li><li><p class="s2" style="padding-left: 27pt;text-indent: -21pt;text-align: justify;">P.M. Rothwell, A. Buchan and S.C. Johnston, Recent ad- vances in management of transient ischemic attacks and mi- nor ischaemic strokes, <i>Lancet Neurol </i><b>5 </b>(2006), 323–331.</p></li></ol><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Appendix 1. Criteria for diagnosis of Menière’s disease. Menière’s disease Research Committee of Japan. 1974.</h1><p class="s10" style="padding-top: 11pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Conditions</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l10"><li><p style="padding-left: 28pt;text-indent: -12pt;text-align: justify;">Repeated attack of whirling vertigo.</p><p style="padding-left: 28pt;text-indent: 0pt;text-align: justify;">Dizzy spells without specific cause which are ac- companied by nausea or vomiting lasting sev- eral minutes to several hours. There may be some episodes of nonwhirling dizziness included in the series of whirling vertigo; mixed types of sponta-</p><p style="padding-top: 4pt;padding-left: 28pt;text-indent: 0pt;text-align: justify;">neous nystagmus (horizontal and rotatory is ob- served in most cases during the attacks; in cases with a single first attack, differential diagnosis with sudden SNHL is specially important.</p></li><li><p style="padding-left: 28pt;text-indent: -12pt;line-height: 11pt;text-align: justify;">Fluctuating cochlear symptoms.</p><p style="padding-left: 28pt;text-indent: 0pt;text-align: justify;">Tinnitus and hearing loss often show fluctuation synchronous with the vertiginous attacks; many patients complain of fullness in the ear and hy- persensitivity to intense sound in the affected ear. The hearing tests reveal a marked fluctuation of the threshold of hearing in the low and middle tone range, recruitment of loudness will be ob- served; usually only one ear is affected, however, bilateral involvement is not rare.</p></li><li><p style="padding-left: 28pt;text-indent: -12pt;text-align: justify;">Exclusion of central nervous system involve- ment, VIIIth nerve tumor and other cochleovesti- bular diseases.</p></li></ol><p style="padding-left: 28pt;text-indent: 0pt;text-align: justify;">To exclude these other disorders, a through his- tory, neurological examination and specific clin- ical examination including equilibrium function tests, audiological tests must be performed some- times it is necessary to follow the patient’s course in order to obtain the required chronological in- formation necessary for establishing the correct diagnosis.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s10" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Diagnostic criteria</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l11"><li><p style="padding-left: 29pt;text-indent: -14pt;text-align: justify;">Definite Menière disease: Condition 1–3.</p></li><li><p style="padding-left: 29pt;text-indent: -14pt;text-align: justify;">Suspicious or uncertain Menière disease 1 and 3 or 2 and 3.</p></li></ol><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-top: 9pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Appendix 2. Menière’s disease diagnostic scale. committee on hearing and equilibrium american academy otolaryngology-head neck surgery. 1995.</h1><p class="s10" style="padding-top: 11pt;padding-left: 5pt;text-indent: 9pt;text-align: justify;">Certain Menière’s disease<span class="p">. Definitive Menière’s dis- ease plus histopathological confirmation</span></p><p class="s10" style="padding-left: 5pt;text-indent: 9pt;text-align: justify;">Definite Menière’s disease. <span class="p">Two or more definitve spontaneous episodes of vertigo lasting 20 minutes or longer, audiometrically documented hearing loss on at least one occasion, tinnitus or aural fullness in the treated ear. Other causes excluded.</span></p><p class="s10" style="padding-left: 5pt;text-indent: 9pt;text-align: justify;">Probable Menière’s disease<span class="p">. One definitive episode of vertigo, audiometrically documented hearing loss on at lest one occasion, tinnitus or aural fullness in the treated ear. Other causes excluded.</span></p><p class="s10" style="padding-left: 5pt;text-indent: 9pt;text-align: justify;">Possible Menière’s disease<span class="p">. Episodic vertigo with- out documented hearing loss or sensorineural hearing loss fluctuating or fixed with disequilibrium but with- out definitive episodes. Other causes excluded.</span></p></body></html>
